Guardant Health Inc. (NASDAQ: GH) saw its stock price surge 5.14% in pre-market trading on Friday, following the release of its better-than-expected first-quarter 2025 financial results and a positive analyst update.
The cancer diagnostics company reported revenue of $203.5 million for Q1 2025, up 21% from the same period last year and exceeding analyst estimates by 7.1%. The company's net loss narrowed to $95.2 million, with a loss per share of $0.77, which was 7.6% better than expected. These strong results demonstrate Guardant Health's continued growth and improving financial performance in the competitive healthcare sector.
Adding to the positive sentiment, Morgan Stanley raised its price target on Guardant Health to $60 from $52, maintaining an Overweight rating on the stock. This upgrade reflects growing confidence in the company's future prospects. Investors appear optimistic about Guardant Health's outlook, with revenue forecast to grow 17% per annum on average over the next three years, outpacing the 7.0% growth forecast for the US Healthcare industry.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。